Supplementary Data 1 from Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial
Eva Ciruelos, A. Prat(Cancer Clinic), Sònia Pernas, Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Antonio Mulero‐Sánchez(Oncode Institute), Lorea Villanueva, Mireia Mele(University of Padua), Santiago Escrivá-de-Romaní(Unknown), Patricia Villagrasa, Juan de la Haba, Álvaro Montaño(Hospital Universitario Virgen del Rocío), Juan Manuel. Ferrero-Cafiero, Tomás Pascual(Cancer Clinic), Javier Cortés, Xavier Gonzalez, Eduardo Martínez, Mafalda Oliveira, Ana Cuadrado Lopez, Patricia Galvan, José Ponce, Antonia Perelló, Esther Sanfeliu, Blanca Cantos(Hospital Universitario Puerta de Hierro Majadahonda)
Cited by 0
Related Papers
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
|The Lancet Oncology|2017|340
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
|EMBO Molecular Medicine|2018|271
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
|The Lancet|2023|225